

AZ 628

Catalog No: **tcsc0091**



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

878739-06-1

Formula:

$C_{27}H_{25}N_5O_2$

Pathway:

MAPK/ERK Pathway

Target:

Raf

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:


451.52

Product Description

AZ628 is a **pan-Raf** kinase inhibitor with **IC₅₀**s of 105, 34 and 29 nM for **B-Raf**, **B-RafV600E**, and **c-Raf-1**, respectively.

IC50 & Target: IC50: 105 nM (B-Raf), 34 nM (B-RafV600E), 29 nM (c-Raf-1)^[1]

In Vitro: AZ628 reduces activities of preactivated B-Raf, B-RafV600E, and c-Raf-1 in in vitro kinase assays, with IC₅₀ values of 105, 34 and 29 nM, respectively. AZ628 also inhibits activation of number of tyrosine protein kinases including VEGFR2, DDR2, Lyn, Flt1, FMS and others. AZ628 inhibits anchorage-dependent and -independent growth, causes cell cycle arrest, and induces apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation^[1]. AZ-628 suppresses growth in cells expressing K-RAS^{G13D}. Inhibition of RAF with AZ-628 suppresses MEK and ERK phosphorylation. AZ-628 selectively affects viability in K-RAS mutant cells^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!